Elisa K Liu1, Erik P Sulman2,3, Patrick Y Wen4, Sylvia C Kurz5,6. 1. New York University Grossman School of Medicine, New York, NY, USA. 2. Department of Radiation Oncology, New York University Grossman School of Medicine, New York, NY, USA. 3. Brain and Spine Tumor Center, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, 240 E. 38th Street, 19th floor, New York, NY, 10019, USA. 4. Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 5. Brain and Spine Tumor Center, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, 240 E. 38th Street, 19th floor, New York, NY, 10019, USA. Sylvia.Kurz@nyulangone.org. 6. Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA. Sylvia.Kurz@nyulangone.org.
Abstract
PURPOSE OF REVIEW: Glioblastoma (GBM) is the most common malignant primary brain tumor, and the available treatment options are limited. This article reviews the recent preclinical and clinical investigations that seek to expand the repertoire of effective medical and radiotherapy options for GBM. RECENT FINDINGS: Recent phase III trials evaluating checkpoint inhibition did not result in significant survival benefit. Select vaccine strategies have yielded promising results in early phase clinical studies and warrant further validation. Various targeted therapies are being explored but have yet to see breakthrough results. In addition, novel radiotherapy approaches are in development to maximize safe dose delivery. A multitude of preclinical and clinical studies in GBM explore promising immunotherapies, targeted agents, and novel radiation modalities. Recent phase III trial failures have once more highlighted the profound tumor heterogeneity and diverse resistance mechanisms of glioblastoma. This calls for the development of biomarker-driven and personalized treatment approaches.
PURPOSE OF REVIEW: Glioblastoma (GBM) is the most common malignant primary brain tumor, and the available treatment options are limited. This article reviews the recent preclinical and clinical investigations that seek to expand the repertoire of effective medical and radiotherapy options for GBM. RECENT FINDINGS: Recent phase III trials evaluating checkpoint inhibition did not result in significant survival benefit. Select vaccine strategies have yielded promising results in early phase clinical studies and warrant further validation. Various targeted therapies are being explored but have yet to see breakthrough results. In addition, novel radiotherapy approaches are in development to maximize safe dose delivery. A multitude of preclinical and clinical studies in GBM explore promising immunotherapies, targeted agents, and novel radiation modalities. Recent phase III trial failures have once more highlighted the profound tumor heterogeneity and diverse resistance mechanisms of glioblastoma. This calls for the development of biomarker-driven and personalized treatment approaches.
Entities:
Keywords:
CAR T cells; Checkpoint inhibitors; Glioblastoma; PARP inhibitors; Radiation; Radiosensitizers
Authors: B Mavroidi; A Kaminari; K Makrypidi; A Shegani; P Bouziotis; I Pirmettis; M Papadopoulos; M Sagnou; M Pelecanou Journal: Invest New Drugs Date: 2022-01-13 Impact factor: 3.651
Authors: Marta Orlicka-Płocka; Agnieszka Fedoruk-Wyszomirska; Dorota Gurda-Woźna; Paweł Pawelczak; Patrycja Krawczyk; Małgorzata Giel-Pietraszuk; Grzegorz Framski; Tomasz Ostrowski; Eliza Wyszko Journal: Antioxidants (Basel) Date: 2021-06-12